Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT04506138
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Esophageal Squamous Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab 200mg D1, D22
  • Paclitaxel for Injection (Albumin Bound) — DRUG
    Paclitaxel for Injection (Albumin Bound) 100mg/m\^2 D1, D8, D22, D29
  • Carboplatin — DRUG
    Carboplatin AUC5 D1, D22

Study Details

This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma

Key Dates

Start date
Aug 11, 2020
Status verified
Dec 2021
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
46 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab plus Chemotherapy

Primary Outcome Measure

Pathologic complete remission (PCR) [ Time Frame: 12 weeks ]

Related Studies